乳腺癌新辅助化疗后残留灶分型与ER、PR、HER-2的关系

王姝姝; 张毅; 齐晓伟; 陈庆秋; 姜军

您当前的位置：

首页 >

文章列表页 >

乳腺癌新辅助化疗后残留灶分型与ER、PR、HER-2的关系

论著 | 更新时间：2026-01-09

- 乳腺癌新辅助化疗后残留灶分型与ER、PR、HER-2的关系
- Correlation of types of residual tumor with expressions of ER, PR and HER-2 after neoadjuvant chemotherapy in breast cancer
- 陆军军医大学学报 2010年32卷第21期页码：2336-2339
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  中图分类号： R730.23;R730.53
- 纸质出版：2010
- 稿件说明：
移动端阅览
王姝姝,张毅,齐晓伟,陈庆秋,姜军.乳腺癌新辅助化疗后残留灶分型与ER、PR、HER-2的关系[J].陆军军医大学学报(原第三军医大学学报),2010,32(21):2336-2339.

　Wang Shushu,Zhang Yi,Qi Xiaowei,Chen Qingqiu,Jiang Jun.Correlation of types of residual tumor with expressions of ER, PR and HER-2 after neoadjuvant chemotherapy in breast cancer[J].J Amry Med Univ (J Third Mil Med Univ),2010,32(21):2336-2339.
王姝姝,张毅,齐晓伟,陈庆秋,姜军.乳腺癌新辅助化疗后残留灶分型与ER、PR、HER-2的关系[J].陆军军医大学学报(原第三军医大学学报),2010,32(21):2336-2339. DOI：

　Wang Shushu,Zhang Yi,Qi Xiaowei,Chen Qingqiu,Jiang Jun.Correlation of types of residual tumor with expressions of ER, PR and HER-2 after neoadjuvant chemotherapy in breast cancer[J].J Amry Med Univ (J Third Mil Med Univ),2010,32(21):2336-2339. DOI：

摘要

目的探讨新辅助化疗后乳腺癌残留灶分型与雌激素受体、孕激素受体及人表皮生长因子受体2的关系。方法 90例Ⅱ、Ⅲ期浸润性导管癌患者手术标本取半，制成全乳腺次连续大切片，显微镜下观察新辅助化疗后乳腺癌残留灶形态并分型；免疫组化检测乳腺癌化疗前后雌激素受体（estrogen receptor

ER)、孕激素受体（progesterone receptor

PR)、人表皮生长因子受体2（human epidermal growth factor receptor

HER-2)状态，并分析残留灶不同分型与新辅助化疗前、新辅助化疗后ER、PR、HER-2的表达水平及其变化情况的相关性。结果新辅助化疗后镜下残留灶可分为3型:Ⅰ型（向心性收缩的孤立性残留癌灶）、Ⅱ型（多灶性斑片状癌灶）、Ⅲ型（主残留病灶旁有卫星结节样残留），分别占61%（55/90）、33%(30/90)、6%（5/90）。残留灶不同分型与新辅助化疗前及新辅助化疗后ER、PR、HER-2表达水平无显著差异（P0.05）；残留灶不同分型与新辅助化疗后ER、PR、HER-2表达水平的变化无显著差异（P0.05）。新辅助化疗后，ER、PR、HER-2表达水平降低，但无统计学差异（P0.05）。结论 ER、PR及HER-2不能评估新辅助化疗后乳腺癌残留灶形态类型，应该进一步结合MRI与全乳大切片进行研究，便于术前了解残留癌灶的基本形态。

Abstract

Objective To study the correlation between types of residual tumor and expressions of ER

PR and HER-2 after neoadjuvant chemotherapy for breast cancer. Methods Samples were collected from 90 women with stages Ⅱ and Ⅲ invasive ductal carcinoma through mastectomy. The samples were cut into sub-serial section of total breast. The morphology of residual tumor was observed and typed under microscope after neoadjuvant chemotherapy. Expressions of ER

PR and HER-2 was detected by immunohistochemistry (IHC). Correlation between expression levels of ER

PR and HER-2 in different types of residual tumor was analyzed before and after neoadjuvant chemotherapy. Results The residual tumor was divided into typeⅠ(solitary residual tumor)

typeⅡ(multifocal residual tumor) and type Ⅲ(main mass with smaller satellite nodules)

accounting for 61% (55/90)

33% (30/90) and 6% (5/90)

respectively. No significant difference was observed in expression levels of ER

HER-2 before and after neoadjuvant chemotherapy (P0.05). The expression levels of ER

PR and HER-2 were lower after neoadjuvant chemotherapy than before neoadjuvant chemotherapy. Conclusion ER

PR and HER-2 cannot be used to evaluate the types of residual tumor after neoadjuvant chemotherapy. MRI in combination with sub-serial section of total breast should be used to show the morphology of residual tumor before operation.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

乳腺癌超声图像特征与ER、PR、CerbB-2的相关性研究

乳腺癌循环肿瘤细胞与原发肿瘤临床病理特征关系的初步研究

老年乳腺癌ER、PR表达及其与临床病理的关系

基于中国人群的雌激素受体表达新分层（低/中/高）可更精准地预测HR⁺/HER2^-早期乳腺癌患者的预后

雌激素受体阳性型乳腺癌新辅助化疗效果的影响因素及疗效预测